Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer
Ekamjit S. Deol, Kristen M. Sanfilippo, Suhong Luo, Mark A. Fiala, Tanya M. Wildes, Hira Mian, Martin W. Schoen
Topics & Concepts
EnzalutamideMedicineProstate cancerPropensity score matchingVeterans AffairsInternal medicineAbirateroneOncologyAdverse effectCancerAndrogen receptorProstate Cancer Treatment and ResearchFrailty in Older AdultsProstate Cancer Diagnosis and Treatment